AWH
NASDAQAspira Women's Health Inc.
SectorHealth CareIndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
News · 26 weeks2+100%
2025-12-212026-06-14
Mix290d
- Market2(100%)
Latest news
25 items- NEWSAspira Women's Health and Cleveland Clinic Expand Strategic Collaboration to Advance AI-Powered Diagnostics in Women's HealthCollaboration aims to accelerate biomarker discovery, strengthen translational research capabilities, and support scalable clinical validation AUSTIN, TX AND CLEVELAND, OH / ACCESS Newswire / May 26, 2026 / Aspira Women's Health Inc. (OTCQX:AWHL) ("Aspira" or the "Company"), a bio-analytical company focused on the development of AI-powered, noninvasive diagnostics for women's health, and Cleveland Clinic have signed an agreement to improve women's health diagnostics.Under the terms of this Master Collaboration and License Agreement, Aspira and Cleveland Clinic will collaborate on research projects focused on the discovery and validation of novel biomarker signatures and the development of ad
- NEWSAspira Women's Health (OTCQB:AWHL) Enters Key Growth Phase with Molecular Lab Expansion to Accelerate Breakthrough Endometriosis Blood Test ENDOinform(TM)AUSTIN, TX / ACCESS Newswire / April 23, 2026 / Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI-enhanced bio-analytics company focused on the development of noninvasive gynecologic disease diagnostics and disease management tools, today announced it is completing the buildout of its molecular laboratory in Q2 2026, marking a major operational milestone that accelerates development and future commercialization of its high-potential endometriosis diagnostic, ENDOinform™.This expansion represents a critical step toward scale, enabling Aspira to advance clinical validation, enhance assay performance, and position the Company for broader market penetration within a multi-billion-dollar
- NEWSAspira Announces Third Quarter 2025 Financial Results and Provides Business UpdateAUSTIN, TX / ACCESS Newswire / November 14, 2025 / Aspira Women's Health Inc. ("Aspira") (OTCQX:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announced today its results of operations for the three and nine-month periods ended September 30, 2025.September Q3 Highlights:Aspira reported relatively flat total product revenues of $2.3 million for the third quarters of 2025 and 2024. The average unit price per test ("AUP") grew 7.0% year-over-year for the commercial product portfolio, comprised of non-invasive Ovarian cancer risk assessment diagnostics marketed as Ova1Plus™ an
- NEWSAspira Women's Health Wins Laboratory Service Contract with University of Texas Medical Branch at GalvestonAspira Executes New, Scalable Laboratory Services Agreement in One of the Largest Markets in the US AUSTIN, TX AND WASHINGTON, DC / ACCESS Newswire / October 29, 2025 / Aspira Women's Health Inc., abio-analytical-based women's health company focused on gynecologic disease diagnostics, today announced it has executed a new laboratory services agreement with University of Texas Medical Branch at Galveston ("UTMB Galveston"), a part of the University of Texas System.The initial term of the agreement is 12 months and is part of the Company's redefined marketing strategy that has prioritized marketing the Company's health care solutions to larger organizations that enable Aspira to efficiently re
- NEWSAspira Women's Health Announces Equity Capital Infusion of $3.06 Million in Private Placement and Warrant Exercise$2.95 Million PIPE$112 thousand warrant exercise AUSTIN, TX / ACCESS Newswire / September 18, 2025 / Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostics and disease management tools, today announced that it has received equity capital totaling $3.06 million from existing and new investors. The company has entered into a securities purchase agreement dated September 18, 2025, pursuant to which the Company has sold and issued an aggregate principal amount of $2.95 million in the form of a Unit Purchase, which includes Common Stock and a partial Warrant (the "Unit"
- NEWSAspira Women's Health Appoints New Chief Financial OfficerNew Executive Brings 20+ Years of Accounting,Capital Markets & Biotechnology Experience AUSTIN, TX / ACCESS Newswire / September 4, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (QTCQB:AWHL), an AI enhanced bio-analytical based women's health company focused on delivering the leading tools critical to gynecologic disease diagnostics and disease management, today announced the appointment of Brian Hungerford as Chief Financial Officer, effective September 2, 2025."We are pleased to announce the addition of Mr. Hungerford to our executive team," commented Mike Buhle, CEO of Aspira. "As our new CFO, he brings a strong combination of financial expertise, strategic vision, and ope
- NEWSAspira Announces Second Quarter 2025 Financial Results and Provides Business UpdateAUSTIN, TX / ACCESS Newswire / August 13, 2025 / Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announced today its results of operations for the three and six months ended June 30, 2025. The Company also reported early progress under its new leadership team.Second Quarter Highlights:Aspira reported total product revenue of $2.404 million in the second quarter of 2025 as compared to $2.423 million in the second quarter of 2024. Reported average unit prices ("AUP") grew 12% year over year for the commercial product portfolio, whi
- NEWSAspira Women's Health Announces Appointment of Jane Pine Wood to the Board of DirectorsAUSTIN, TX / ACCESS Newswire / July 15, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (QTCQB:AWHL), an AI enhanced bio-analytical based women's health company focused on delivering the leading tools critical to gynecologic disease diagnostics and disease management, today announced the appointment of Jane Pine Wood to the Board of Directors, effective July 11, 2025."We are pleased to welcome Jane Pine Wood to the Board of Directors," said Jack Fraser, Chairman of the Board of Directors of Aspira Women's Health. "Ms. Wood brings a remarkable track record of representing a wide range of healthcare providers - including clinical and anatomic laboratories, hospitals, health syste
- NEWSAspira Women's Health Partners with Dorsata to Offer Access to 300+ Women's Health Practices, 1.5 Million + New PatientsAspira and Dorsata Launch Clinical Workflow Tool for Adnexal Masses,Now Live for All Dorsata Clients, Adnexal Mass Evidence-Based Decision Support AUSTIN, TX AND WASHINGTON, DC / ACCESS Newswire / June 17, 2025 / Aspira Women's Health Inc. a bio-analytical-based women's health company focused on gynecologic disease diagnostics, and Dorsata, a leading clinical decision-support and provider workflow platform for women's health, announced today the official launch of a new adnexal mass clinical decision support module in partnership with Dorsata, a leading women's health electronic health record software solutions company.Dorsata's platform is currently used by more than 700 women's health prov
- NEWSAspira Women's Health Provides Update on ARPA-H Sprint Program Partnership to Advance Women's HealthAUSTIN, TX AND WASHINGTON, DC / ACCESS Newswire / June 11, 2025 / Aspira Women's Health Inc., ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announces an update from the Advanced Research Projects Agency for Health's ( ARPA-H ) Sprint for Women's Health program initiative to address critical unmet needs in women's health.Aspira was originally awarded a $10 Million award through ARPA-H's Sprint for Women's Health to support the development of Aspira's ENDOinform test, a non-invasive blood draw-based multi-omics test utilizing protein and microRNA biomarker
- NEWSAspira Announces First Quarter 2025 Financial Results and Provides Business UpdateAUSTIN, TX / ACCESS Newswire / May 19, 2025 / Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announced today its results of operations for the three-month period ended March 31, 2025. The Company also reported early progress under its new leadership team. Key financial highlights for the quarter are summarized below:Revenue Growth: The Company generated approximately $2.28 million of revenue for the quarter ending March 31, 2025, compared to $2.15 million in the first quarter of 2024. The 5.9% increase was primarily driven by se
- NEWSAspira Successfully Completes Application to the OTCQBAUSTIN, TX / ACCESS Newswire / May 7, 2025 / Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering the leading tools critical to gynecologic disease diagnostics and disease management, today announced it has successfully completed the process of transitioning to the OTCQB markets exchange. The Company begins trading on the OTCQB marketplace today, May 7, 2025."This is a positive next step for Aspira and our shareholders," commented Mike Buhle, CEO of Aspira. "Our decision to prioritize OTCQB was carefully considered for the benefit of our current and future shareholders. We have focused heavily on cost reduction, t
- NEWSAspira Reaches Another ARPA-H Milestone, Eligible to Receive Additional $1.5 Million in Second QuarterAspira Women's Health Submits the Third Milestone of ARPA-H $10 Million Award AUSTIN, TX / ACCESS Newswire / May 1, 2025 / Aspira Women's Health Inc. ("Aspira") (OTC:AWHL), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the successful submission of its third development milestone of its Advanced Research Projects Agency for Health (ARPA-H) award.The third milestone focused heavily on additional analytical development steps. The milestone specifically required the completion of additional deliverables including a biomarker technical report, as well as the framework for a voice of customer study. Aspira is now
- SECAmendment: SEC Form S-1/A filed by Aspira Women's Health Inc.S-1/A - Aspira Women's Health Inc. (0000926617) (Filer)
- INSIDERNew insider Fraser John D claimed ownership of 841,558 shares (SEC Form 3)3 - Aspira Women's Health Inc. (0000926617) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hundorfean Cynthia D3 - Aspira Women's Health Inc. (0000926617) (Issuer)
- SECSEC Form DEFR14A filed by Aspira Women's Health Inc.DEFR14A - Aspira Women's Health Inc. (0000926617) (Filer)
- NEWSAspira Women's Health Inc. to Begin Trading April 17th On OTC Under the Symbol "AWHL"SHELTON, CT / ACCESS Newswire / April 17, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that at beginning of trading on April 17, 2025, the Company expects that its Common Stock will begin trading under its new symbol "AWHL" on markets operated by the OTC Markets Group, Inc. This symbol replaces the prior symbol "AWH" under which the Company previously traded.About Aspira Women's Health Inc. Aspira Women's Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagn
- SECAspira Women's Health Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - Aspira Women's Health Inc. (0000926617) (Filer)
- NEWSAspira Women's Health Inc. Announces Receipt of Delisting Notification from NasdaqSHELTON, CT / ACCESS Newswire / April 16, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that on April 15, 2025, the Company received written notice (the "Notice") from the Office of General Counsel of The Nasdaq Stock Market ("Nasdaq") indicating that the Nasdaq Hearings Panel has determined to delist the Company's shares from Nasdaq due to the Company's failure to meet Nasdaq's continued listing standards. As previously disclosed, the Company has not been compliant with the requirements under Nasdaq Listing Rule 5550(b)(1) to maintai
- SECSEC Form S-1 filed by Aspira Women's Health Inc.S-1 - Aspira Women's Health Inc. (0000926617) (Filer)
- SECSEC Form DEF 14A filed by Aspira Women's Health Inc.DEF 14A - Aspira Women's Health Inc. (0000926617) (Filer)
- SECAspira Women's Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Other Events, Financial Statements and Exhibits8-K - Aspira Women's Health Inc. (0000926617) (Filer)
- NEWSAspira Appoints Three New Directors, Executes $2.0 Million Equity Purchase AgreementNew Directors Bring Extensive Commercial Healthcare Relationships to Expand Business Development Opportunities. AUSTIN, TX / ACCESS Newswire / April 8, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of three new Directors to its Board of Directors. These appointments were part of a planned Board change, aligned with the upcoming annual shareholders meeting. Each of the three new appointees brings extensive resumes, with the first two Directors, Dr. Jeffrey Cohen and Cindy Hundorfean, bringing decades of experience in
- INSIDERDirector Vos Ellen O'Connor converted options into 5,313 shares, increasing direct ownership by 8% to 68,677 units (SEC Form 4)4 - Aspira Women's Health Inc. (0000926617) (Issuer)
AWH FAQ
6 questionsWhat does Aspira Women's Health Inc. do?
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. It provides OVA1, Overa, and Ova1PLUS to detect the risk of ovarian malignancy. The company also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, it owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic...Where does AWH stock trade?
Aspira Women's Health Inc. (AWH) is listed on NASDAQ.What sector and industry is AWH in?
Aspira Women's Health Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.What are analysts saying about AWH?
Aspira Women's Health Inc. has had 1 recent analyst action on file. The most recent action was from Cantor Fitzgerald: Overweight with a $400.00 price target on 2022-01-12. Recent price targets cluster around $400.00.What companies are similar to AWH?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), ORKA (Oruka Therapeutics Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), CLDX (Celldex Therapeutics Inc.). Compare AWH side-by-side with any of them on Quantisnow.How can I track AWH on Quantisnow?
Quantisnow aggregates Aspira Women's Health Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AWH to receive live email and push alerts on every new disclosure.